多西他赛或紫杉醇联合奈达铂在宫颈癌辅助化疗中的疗效及安全性分析

目的:观察和比较多西他赛或紫杉醇联合奈达铂辅助化疗治疗宫颈癌患者的临床疗效及其安全性。方法:选择45例采用多西他赛联合奈达铂化疗的宫颈癌患者为观察组及45例同期采用紫杉醇联合奈达铂化疗的宫颈癌患者作为对照组,两组均行手术治疗,且术前接受辅助化疗。对比两组临床疗效、手术时间和术后病理状况及不良反应的发生情况。结果:化疗后,观察组临床有效率高于对照组(62.22%vs.55.56%),但组间比较差异无统计学意义(P0.05)。化疗期间,观察组恶心、呕吐、腹痛、腹泻、白细胞、中性粒细胞减少、血红蛋白和血小板减少的发生率均低于对照组,但组间比较差异均无统计学意义(P0.05);观察组神经毒性发生率明显低于对照组,组间比较差异有统计学意义(P0.05)。化疗后,行手术治疗,观察组手术时间低于对照组,但组间比较差异无统计学意义(P0.05);手术后,观察组盆腔淋巴结转移率和宫旁浸润率低于对照组,但组间比较差异无统计学意义(P0.05)。结论:多西他赛联合奈达铂辅助化疗宫颈癌的疗效与紫杉醇联合奈达铂相当,且神经毒性、骨髓抑制方面的发生率明显降低,是临床低毒性且有效的宫颈癌术前新辅助化疗方案。

Analysis of the Efficacy and safety of Docetaxel or Paclitaxel combined with Nedaplatin in the Adjuvant Chemotherapy of Cervical Cancer

ABSTRACT Objective: To observe and compare the clinical efficacy and safety of docetaxel and paclitaxel combined with nedaplatin in the treatment of cervical cancer. Methods: Forty-five patients with cervical cancer treated with docetaxel and nedaplatin were selected as the observation group and 45 patients with cervical cancer treated with paclitaxel and nedaplatin were selected as as the control group. The clinical efficacy, operative time, postoperative pathological conditions and incidence of adverse reactions were compared between the two groups. Results: After chemotherapy, the clinical efficiency of observation group was higher than that of the control group (62.22% vs. 55.56%), but there was no significant difference between the two groups (P>0.05). During chemotherapy, the incidence of nausea, vomiting, abdominal pain, diarrhea, leukopenia, neutropenia, hemoglobin and thrombocytopenia in the observation group were lower than those in the control group, but there was no significant difference between the two groups(P>0.05). During chemotherapy, the incidence of neurotoxicity, leukopenia and neutropenia in the observation group were significantly lower than those in the control group(P<0.05), the incidence of hemoglobin reduction and thrombocytopenia in the observation group was lower than that in the control group, but there was no significant difference between the two groups(P>0.05). There was no significant difference in the operation time between the two groups(P>0.05). After operation, the rate of pelvic lymph node metastasis and uterine infiltration in the observation group were lower than those in the control group(P>0.05). Conclusion: The efficacy of docetaxel combined with nedaplatin in the treatment of cervical cancer is similar to that of paclitaxel combined with nedaplatin, but the incidence of neurotoxicity and myelosuppression is significantly lower, which is a clinical low toxicity and effective neoadjuvant chemotherapy for cervical cancer.